Rigel Pharmaceuticals Inc (RIGL) stock
RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
$44.46−1.23 (-2.69%)
Close on Nov 13, 2026Market cap $830.51MP/E 2.9Yield –
Rigel Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Rigel Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $54.59M, up 93.3% year over year. For fiscal 2025 it was $33.30M, up 42.4% from the year before. Over ten years it grew -6.2% a year on average. The highest annual figure on record is $90.74M in fiscal 2009.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.30M | +42.4% |
| FY2024 | Dec 31, 2024 | $23.38M | -4.7% |
| FY2023 | Dec 31, 2023 | $24.52M | -59.3% |
| FY2022 | Dec 31, 2022 | $60.27M | -7.6% |
| FY2021 | Dec 31, 2021 | $65.24M | +8.5% |
| FY2020 | Dec 31, 2020 | $60.10M | +13.6% |
| FY2019 | Dec 31, 2019 | $52.89M | +12.8% |
| FY2018 | Dec 31, 2018 | $46.90M | +1.4% |
| FY2017 | Dec 31, 2017 | $46.27M | -27.1% |
| FY2016 | Dec 31, 2016 | $63.45M | +1.0% |
| FY2015 | Dec 31, 2015 | $62.83M | -7.2% |
| FY2014 | Dec 31, 2014 | $67.70M | -10.1% |
| FY2013 | Dec 31, 2013 | $75.33M | -4.4% |
| FY2012 | Dec 31, 2012 | $78.78M | +13.6% |
| FY2011 | Dec 31, 2011 | $69.35M | +7.7% |
| FY2010 | Dec 31, 2010 | $64.39M | -29.0% |
| FY2009 | Dec 31, 2009 | $90.74M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $18.27M | +148.5% |
| Q2 FY2026 | Jun 30, 2026 | $13.96M | +104.7% |
| Q1 FY2026 | Mar 31, 2026 | $11.68M | +38.4% |
| Q4 FY2025 | Dec 31, 2025 | $10.69M | +89.7% |
| Q3 FY2025 | Sep 30, 2025 | $7.35M | +18.9% |
| Q2 FY2025 | Jun 30, 2025 | $6.82M | +23.1% |
| Q1 FY2025 | Mar 31, 2025 | $8.44M | +40.0% |
| Q4 FY2024 | Dec 31, 2024 | $5.63M | +76.8% |
| Q3 FY2024 | Sep 30, 2024 | $6.18M | -4.5% |
| Q2 FY2024 | Jun 30, 2024 | $5.54M | +16.1% |
| Q1 FY2024 | Mar 31, 2024 | $6.03M | -40.3% |
| Q4 FY2023 | Dec 31, 2023 | $3.19M | -79.3% |
| Q3 FY2023 | Sep 30, 2023 | $6.48M | -55.9% |
| Q2 FY2023 | Jun 30, 2023 | $4.77M | -67.7% |
| Q1 FY2023 | Mar 31, 2023 | $10.09M | -34.8% |
| Q4 FY2022 | Dec 31, 2022 | $15.37M | +15.5% |
| Q3 FY2022 | Sep 30, 2022 | $14.67M | -19.9% |
| Q2 FY2022 | Jun 30, 2022 | $14.77M | -12.1% |
| Q1 FY2022 | Mar 31, 2022 | $15.47M | -8.0% |
| Q4 FY2021 | Dec 31, 2021 | $13.30M | -12.1% |
| Q3 FY2021 | Sep 30, 2021 | $18.30M | +25.3% |
| Q2 FY2021 | Jun 30, 2021 | $16.81M | +18.2% |
| Q1 FY2021 | Mar 31, 2021 | $16.83M | +4.2% |
| Q4 FY2020 | Dec 31, 2020 | $15.14M | +6.3% |
| Q3 FY2020 | Sep 30, 2020 | $14.60M | +0.9% |
| Q2 FY2020 | Jun 30, 2020 | $14.21M | +7.5% |
| Q1 FY2020 | Mar 31, 2020 | $16.15M | +47.5% |
| Q4 FY2019 | Dec 31, 2019 | $14.25M | +3.5% |
| Q3 FY2019 | Sep 30, 2019 | $14.46M | +30.3% |
| Q2 FY2019 | Jun 30, 2019 | $13.23M | +22.5% |
| Q1 FY2019 | Mar 31, 2019 | $10.95M | -2.6% |
| Q4 FY2018 | Dec 31, 2018 | $13.77M | +19.1% |
| Q3 FY2018 | Sep 30, 2018 | $11.10M | +2.7% |
| Q2 FY2018 | Jun 30, 2018 | $10.80M | -6.3% |
| Q1 FY2018 | Mar 31, 2018 | $11.24M | -9.2% |
| Q4 FY2017 | Dec 31, 2017 | $11.56M | -0.6% |
| Q3 FY2017 | Sep 30, 2017 | $10.81M | – |
| Q2 FY2017 | Jun 30, 2017 | $11.52M | – |
| Q1 FY2017 | Mar 31, 2017 | $12.38M | – |
| Q4 FY2016 | Dec 31, 2016 | $11.63M | – |
See a number that looks wrong?